ACTRN12619000047190已完成1 期
Pentosan Polysulphate (PPS) for Dyslipidaemia in Knee Osteoarthritis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 45 Years 至 o limit（—）
- 性别
- All
入选标准
- •A.Male or female patients minimum of 45 years or more;
- •B.Are able to give written informed consent and to participate fully in the interventions and follow-up procedures including travel to the Royal North Shore Hospital;
- •C.Have history of primary hypercholesterolemia and total fasting cholesterol above 5.0mmol/L at screening;
- •D.Have any symptoms associated with OA of the knee for at least 6 months prior to screening visit and confirmation of OA based on the clinical and radiological criteria of American College of Rheumatology Criteria for OA (Altman et al, 1986) of the knee prior or at screening.
- •E.Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee based on knee radiograph performed at screening or within six months of the screening visit;
- •F.Have Index knee pain on most days over the last month.
- •G.Knee Pain Severity Scale above 4 using an 11-point (0-10) numerical severity scale where 0 is no pain at all and 10 is worst possible pain in the last 48 hours at baseline visit;
- •(If both knees are affected by OA then the most symptomatic knee will be considered the index knee. If both knees are equally affected, the index knee will be determined by the Investigator.)
- •H.BMI<40 kg/m2 at screening visit;
- •I.Agree to maintain their usual activity level and diet throughout the study;
- •J.Female of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation;
排除标准
- •A.Documented history of Fibromyalgia, Reiter’s syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease;
- •B.Known hypersensitivity to Pentosan Polysulfate or related compounds (e.g. heparin);
- •C.Any unstable concurrent clinically significant acute, chronic medical conditions or abnormal laboratory findings that, in the judgment of the Investigator, would jeopardise the safety of the patient, interfere with the objectives of the protocol, or affect the patients compliance with the study requirements, as determined by the investigator;
- •D.Contraindications for MRI including but not limited to pacemaker, metal sutures, presence of shrapnel, or claustrophobia;
- •E.Current or a recent history (within last 12 months) of bleeding (a gastric or duodenal ulcer or suspicion of GI tract bleeding) or menorrhagia;
- •F.Haemophilia ;
- •G.Planned / anticipated invasive procedure (or surgery) within 6 months;
- •H.Recent surgery;
- •I.Bilateral Knee replacement
- •J.Concurrent heparin or oral anti-coagulant therapy;
- •K.Concurrent therapy with lipid –modifying drugs for hypercholesterolemia;
- •L.Female patients who are pregnant, nursing or intend to get pregnant;
- •M. Use of prohibited pain medication( see below)
- •Oral non-steroidal anti-inflammatory drugs (NSAIDs)
- •Aspirin (>325 mg per day)
- •Centrally-acting pain medications (e.g., pregabalin, gabapentin, duloxetine)
- •Opioids (e.g. tramadol)
- •Topical therapies (e.g., NSAIDs ) applied to the index knee
- •Muscle relaxants (e.g. tetrazepam, diazepam)
- •N. Prohibited Concomitant Medications:
- •Lipid-modifying drugs: statins ( e.g. atorvastatin, pravastatin and simvastatin) or ezetimibe (Ezetrol)
- •Anticoagulants including heparin, warfarin, apixaban (Eliquis), dabigatran (Pradaxa) and rivaroxaban (Xarelto)
- •Biological/ disease –modifying anti-rheumatic drugs for arthritis
- •Steroid drugs for systematic use
研究者
相似试验
进行中（未招募）
不适用
Glukosaminsulfat og hyperkolesterolæmiOsteoarthritisEUCTR2005-000541-11-DKSlidgigtinstituttet A/S66
已完成
不适用
Efficacy Study of Pentosan Polysulfate Sodium,Hydrodistension and Combination Therapy for Bladder Pain SyndromeBladder Pain SyndromePentosan PolysulfateHydrodistensionNCT01895153Samsung Medical Center91
已完成
不适用
Efficacy and safety of PCSK9 inhibitor for dyslipidemiarefractory dyslipidemiaJPRN-UMIN000023483Sekino Hospital70
已完成
不适用
Investigation for the effect of anti-dyslipidemic drugs on serum level of trans-fatty acidsdyslipidemiaJPRN-UMIN000026984Kobe University Graduate School of Medicine40
已完成
不适用
Plasma pentosidine is associated with cardiovascular events in hemodialysis patients.Chronic renal failureJPRN-UMIN000005452Iwata City Hospital100